FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569081491> ?p ?o ?g. }

• W1569081491 abstract "Ankle osteoarthritis (OA) is a degenerative joint disease that can cause substantial pain, muscle weakness and functional limitations. Due chiefly to its post-traumatic origin and appearance in young patients, ankle OA has a high impact on socioeconomics and patients’ quality of life. Approximately 6% to 13% of all cases of OA involve the ankle joint (Thomas and Daniels, 2003). Recent research also identify that a larger number of patients are being diagnosed with ankle OA (Saltzman et al, 2005). Currently, no curative therapy is available for OA, and thus the overall goals of management are to reduce pain and prevent disability. Treatment options include simple analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), weight reduction, physical and occupational therapy, activity modification, orthotic devices, shoe modifications, intraarticular corticosteroid injections, and surgery. Although some cases can be treated successfully with surgery, many patients are either not good candidates for surgery or may want to avoid or delay it if possible. There is a need for a treatment that reduces chronic joint pain and improves function yet avoids toxic effects of medications and the morbidity and mortality risks of surgery. One such option for these patients may be the intraarticular injection of hyaluronate. Hyaluronate, a high molecular weight polysaccharide, is a principal component of synovial fluid and extracellular matrix of articular cartilage. It contributes to the elasticity and viscosity of synovial fluid. In addition to providing joint lubrication and shock absorbancy, hyaluronate helps to maintain the structural and functional characteristics of the cartilage matrix. It also inhibits the formation and release of prostaglandins, induces proteoglycan aggregation and synthesis, and modulates the inflammatory response (Frizziero, 1998). In OA, the concentration and molecular weight of hyaluronate are reduced, limiting its role in maintaining normal joint biomechanics (Engstrom-Laurent A, 1997). Viscosupplementation with intraarticular injections of hyaluronate was approved by the Food and Drug Administration (FDA) in 1997 for treating pain associated with knee OA. Although the exact mechanism of action is not understood with certainty, recent research suggests that it exerts anti-inflammatory, analgesic, anabolic and possibly chondroprotective effects on the articular cartilage and joint synovium that reduce pain and disability and improve joint function." @default.
• W1569081491 created "2016-06-24" @default.
• W1569081491 creator A5017114719 @default.
• W1569081491 creator A5020836737 @default.
• W1569081491 creator A5029098848 @default.
• W1569081491 creator A5030099778 @default.
• W1569081491 creator A5043310151 @default.
• W1569081491 date "2012-03-02" @default.
• W1569081491 modified "2023-10-02" @default.
• W1569081491 title "Hyaluronate for the Treatment of Ankle Osteoarthritis" @default.
• W1569081491 cites W144260377 @default.
• W1569081491 cites W1965224215 @default.
• W1569081491 cites W1972158258 @default.
• W1569081491 cites W1980107060 @default.
• W1569081491 cites W1985055656 @default.
• W1569081491 cites W1986603661 @default.
• W1569081491 cites W2006777217 @default.
• W1569081491 cites W2015411374 @default.
• W1569081491 cites W2047707946 @default.
• W1569081491 cites W206042543 @default.
• W1569081491 cites W2082342902 @default.
• W1569081491 cites W2112755074 @default.
• W1569081491 cites W2142238897 @default.
• W1569081491 cites W2151853977 @default.
• W1569081491 doi "https://doi.org/10.5772/26918" @default.
• W1569081491 hasPublicationYear "2012" @default.
• W1569081491 type Work @default.
• W1569081491 sameAs 1569081491 @default.
• W1569081491 citedByCount "0" @default.
• W1569081491 crossrefType "book-chapter" @default.
• W1569081491 hasAuthorship W1569081491A5017114719 @default.
• W1569081491 hasAuthorship W1569081491A5020836737 @default.
• W1569081491 hasAuthorship W1569081491A5029098848 @default.
• W1569081491 hasAuthorship W1569081491A5030099778 @default.
• W1569081491 hasAuthorship W1569081491A5043310151 @default.
• W1569081491 hasBestOaLocation W15690814911 @default.
• W1569081491 hasConcept C141071460 @default.
• W1569081491 hasConcept C142724271 @default.
• W1569081491 hasConcept C1862650 @default.
• W1569081491 hasConcept C204787440 @default.
• W1569081491 hasConcept C2776164576 @default.
• W1569081491 hasConcept C2778640784 @default.
• W1569081491 hasConcept C71924100 @default.
• W1569081491 hasConcept C99508421 @default.
• W1569081491 hasConceptScore W1569081491C141071460 @default.
• W1569081491 hasConceptScore W1569081491C142724271 @default.
• W1569081491 hasConceptScore W1569081491C1862650 @default.
• W1569081491 hasConceptScore W1569081491C204787440 @default.
• W1569081491 hasConceptScore W1569081491C2776164576 @default.
• W1569081491 hasConceptScore W1569081491C2778640784 @default.
• W1569081491 hasConceptScore W1569081491C71924100 @default.
• W1569081491 hasConceptScore W1569081491C99508421 @default.
• W1569081491 hasLocation W15690814911 @default.
• W1569081491 hasLocation W15690814912 @default.
• W1569081491 hasOpenAccess W1569081491 @default.
• W1569081491 hasPrimaryLocation W15690814911 @default.
• W1569081491 hasRelatedWork W2126429866 @default.
• W1569081491 hasRelatedWork W2139095351 @default.
• W1569081491 hasRelatedWork W2168703316 @default.
• W1569081491 hasRelatedWork W2897343059 @default.
• W1569081491 hasRelatedWork W3086885399 @default.
• W1569081491 hasRelatedWork W3136724646 @default.
• W1569081491 hasRelatedWork W3153751189 @default.
• W1569081491 hasRelatedWork W4231122357 @default.
• W1569081491 hasRelatedWork W4288844215 @default.
• W1569081491 hasRelatedWork W3086110545 @default.
• W1569081491 isParatext "false" @default.
• W1569081491 isRetracted "false" @default.
• W1569081491 magId "1569081491" @default.
• W1569081491 workType "book-chapter" @default.